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Abstract 
The United Nations Joint Programme on HIV/AIDS (UNAIDS) has set a target to ensure that 15 million HIV-positive people 
in the world would be receiving combination anti-retroviral treatment (ART) by 2015. This target is likely to be reached and 
new targets for 2020 and 2030 are needed. Eastern and Southern Africa (ESA) account for approximately half of all people 
living with HIV in the world and it will be especially important to set reachable and affordable targets for this region. In order 
to make future projections of HIV and TB prevalence, incidence and mortality assuming different levels of ART scale-up and 
coverage, it is first necessary to assess the current state of the epidemic. Here we review national data on the prevalence of 
HIV, the coverage of ART and the notification rates of TB to provide a firm basis for making future projections. We use the 
data to assess the extent to which behaviour change and ART have reduced the number of people living with HIV who remain 
infectious. 
 
Introduction 
In order to assess the current status and trends in the 
prevalence of HIV, the coverage of ART and the 
notification rates of TB for all the countries in the 
UNAIDS Eastern and Southern Africa (ESA) region we 
start from the UNAIDS model fits1 for HIV and ART and 
the WHO data for TB.2 We fit the HIV data to a double-
logistic function and use the fitted function to estimate the 
impact on the TB epidemic assuming a variable delay and 
incidence rate ratio for TB in people with HIV, with or 
without ART. Where the data appear to be inconsistent we 
refer back to the original data on which the UNAIDS 
model fits were made and adjust the estimates accordingly. 
This gives our best estimates of the current status and 
trends for HIV and TB. It is important to stress that this is 
not a transmission model so that it does not allow for 
reductions in transmission arising from the provision of 
ART. The purpose of this study is to ensure that we have 
the best estimates of the current trend data which can then 
be used to drive a dynamical transmission model. 
Analysis 
For the HIV epidemics we fit a double-logistic function 
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to the reported prevalence data. The first term in Equation 
1 accounts for the rate, r1, the timing t1, and the peak 
prevalence a1 of the initial rise in the prevalence. The 
second term accounts for the rate, r2, the timing t2, and the 
subsequent drop, a2, in the prevalence as a result of 
reductions in transmission not associated with the 
increasing coverage of ART. While we refer to this as 
‘behaviour change’ the reasons for and drivers of these 
reductions in transmission are not understood and we 
discuss this further below. 
  
 
For the ART coverage we fit a single logistic function 
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to the reported coverage data where the rate, r3, the timing 
t3, and the asymptotic prevalence of ART t3, account for 
the increasing coverage of ART. 
 For the TB notification rates we use three parameters: 
the pre-HIV notification rate n, the time delay between the 
rise in ART prevalence and TB notifications, τ, and the 
incidence rate ratio for TB when people are infected with 
HIV, η. We assume that the incidence rate ratio for TB 
when people are on ART is 0.4η.3 The TB notification rate 
is then 
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Results 
Figure 1 gives the data for HIV and TB for each of the 
countries in ESA and the fitted functions (Equations 1−3). 
For HIV the red dots are the UNAIDS estimates of the 
prevalence of HIV; the red lines are the fitted values. The 
green dots are the UNAIDS estimates of the coverage of 
ART; the green lines are the fitted values. The blue lines 
are the red lines minus the green lines and give estimates 
of the prevalence of HIV for people who are not on ART. 
For HIV the denominator is the total adult population aged 
fifteen years or more. 
 For TB the green lines give the notification rate in 
HIV-negative people, the blue lines include the 
notification rate for people infected with HIV but not on 
ART, the red lines include the notification rate for people 
infected with HIV and on ART, that is to say the total 
notification rate. For TB the denominator is the total 
population. 
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Figure 1. HIV prevalence among adults 15+ years old and TB notifications per 100k population for the countries in ESA. HIV: UNAIDS 
estimates of HIV prevalence (red dots) and ART prevalence (green dots). Fitted total prevalence, red lines, prevalence of ART (green lines) 
prevalence for those not on ART (blue lines). TB: WHO estimates of TB notification rates (red dots). Fitted notification rates for HIV 
negative people (green lines); including HIV positive people not on ART (blue lines); including HIV people on ART, that is total notification 
rate, (red lines). 
 The data for the Comoros in Figure 1 are insufficient to 
estimate the trends in either HIV or TB. The HIV data for 
Madagascar show a flat peak followed by a decline which 
is unlike the trend in any other country and this needs to be 
examined further. The data for Angola show a steady rise 
unlike that in any other country and are considered in more 
detail below. The other countries show either a rise to a 
more or less constant asymptote or a peak followed by a 
decline that precedes the roll-out of ART and which we 
attribute to a reduction in the risk of infection due to an 
unspecified change in behaviour. In South Africa, 
Swaziland and Lesotho the prevalence flattens off but 
continues to rise after the year 2000. This slow rise is 
surprising in view of the ante-natal clinic data for South 
Africa which show a flattening of the prevalence of HIV in 
all nine provinces and no indication of a continuing 
increase.4 Here we assume that the prevalence reaches a 
plateau but this too needs further consideration. The data 
for Uganda show a rapid decline followed by a significant 
upturn in the prevalence and this recent increase needs to 
be examined carefully. If it were the case that the decline 
in the prevalence of HIV in Uganda came about because 
an increased awareness of AIDS related mortality then the 
subsequent fall in mortality could produce the upturn as 
shown in a modelling study for Zimbabwe.5 
 We first examine the raw data for Angola. The data on 
which the UNAIDS trend estimates are based (Appendix 
1; Table 1) show the sparse nature of the data for Angola. 
In particular there is one early data point for Zaire 
Province where a prevalence of 9% in was recorded in 
1988 but no further data were available until 2007 after 
which time the prevalence remains below 2.3%. It seems 
prudent to exclude this point.  
 This is followed by a series of estimates ranging from 
5% to 8% in Cabinda between 1992 and 1999. However, 
Cabinda is an enclave separated from Angola by the 
Democratic Republic of the Congo so it seems safe to 
exclude these data also. The only data that allow us to 
estimate the timing and rate of the initial rise in HIV are 
from four data points in Luanda between 1995 and 2001 
and if we use these to set the timing and the rate of the 
initial increase we get the fits shown in Figure 2 which 
appear to be more reasonable than the fits for Angola 
given in Figure 1. 
 
 
 
 
 
 
 
Figure 2. HIV prevalence (%) and TB notifications (per 100k 
population) for Angola. As described in the text this excludes the 
data for Cabinda and Zambia and uses the data from Luanda to 
determine the rate and timing of the initial rise in the prevalence 
of HIV.  
 
 
 
 
 
Figure 3. The fitted HIV prevalence (% of adults 15+ years old) 
and TB notifications (per 100k population) for Angola. For the 
reasons discussed in the text we use the fit to the TB data to 
determine the rise in HIV prevalence assuming a delay between 
the two of 3 years. 
 This still raises questions about the time trend of the 
prevalence of HIV in Angola. We note first (Figure 2 c.f. 
Figure 1) that the epidemic of HIV in Angola appears to 
have risen about five years later than in any other country; 
that the initial rate of increase is 30% greater than in any 
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other country  and the rise in TB predates the rise in HIV 
by 2.7 years which cannot be the case.  
 Since the timing was based on only four points for 
Luanda we therefore set the initial rate of increase to 
0.5/year (the average of all the other countries in the 
region) and set the delay between the rise of HIV and the 
rise of TB to 3 years. This gives the fits shown in Figure 3 
and we use these to describe the trends in HIV and TB for 
Angola. We now consider the values of the fitted 
parameters used in Figure 1, using Figure 3 for Angola, 
and these are given in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Parameters for the fits to the HIV and TB data for the countries in ESA. Top left: The timing of the epidemic as measured by the 
year in which the initial rise reaches half of its asymptotic value. Top right: the peak prevalence of HIV. Row 2, left: The initial rate of 
increase/year. Row 2, right: The proportional reduction in the prevalence of HIV resulting from reductions in transmission preceding the roll-
out of ART. Row 3, left: The proportional reduction in the prevalence as a result of the roll-out of ART. Row 3, right: The time delay 
between the rise of HIV and the rise of TB. Bottom: The estimated values of the incidence rate ratio. 
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Discussion 
The fits in Figure 1, Figure 3 for Angola, provide the 
current best estimates of the trend in HIV, ART and TB 
for the countries of the ESA region and should be used to 
inform dynamical models of HIV and TB with a view to 
projecting future trends and assessing the impact and costs 
of different combinations of interventions. This 
preliminary data cleaning process reveals important 
insights into the nature of the epidemics in ESA which can 
also be used to guide further analysis. 
 With regard to timing (Figure 4, top left) the epidemic 
of HIV started first in the East African countries of 
Uganda, Rwanda, Zambia and Malawi and last in Lesotho, 
Mozambique, Namibia, Swaziland and South Africa. This 
is consistent with the notion that HIV arose first in Central 
Africa and then spread from there to East and then to 
southern Africa. It is likely that the restriction of 
movement and the isolation of South Africa under the 
Apartheid Regime delayed the spread of HIV into South 
Africa and some of the neighbouring states and the war in 
Mozambique, which ended in 1992 1  may have further 
delayed the spread of HIV in that country. 
 The peak prevalence of HIV in the ESA Region 
(Figure 4, top right) varies by an order of magnitude. 
Excluding the island countries the lowest prevalence rates 
of HIV were observed in Angola, Eritrea and Ethiopia; the 
highest in Botswana, Lesotho, Swaziland and Zimbabwe. 
While Swaziland is closely connected to KwaZulu/Natal, 
where the peak prevalence was even higher, Lesotho is 
heavily dependent on remittances from mine workers in 
South Africa. The reasons for the high rates of HIV in 
Botswana and Zimbabwe are less clear. While Batswana 
are employed in significant numbers to work on the mines 
in South Africa, men from Zimbabwe were only ever 
employed on the gold mines in South Africa in small 
numbers. 
 It should be noted that the UNAIDS data suggest that 
in South Africa, Lesotho and Swaziland, the prevalence of 
HIV is still increasing slowly. However, the prevalence of 
HIV among ante-natal clinic women in South Africa has 
been flat for the last five years in all nine provinces so we 
will assume that the apparent slow rise is an artefact of the 
UNAIDS model in South Africa, Lesotho and Swaziland. 
 The countries in which the initial rate of spread was 
fastest (Figure 4, second row, left) were Lesotho, 
Swaziland, South Africa and Kenya. We exclude Angola 
as the early data there are unreliable. The rapid rise in 
Lesotho and Swaziland may have been driven by the 
considerable extent of migration between these two 
countries and South Africa. The reasons for the rapid rise 
in Kenya are less clear but it should be noted that about 
30% of all cases of HIV occur in nine districts in South 
Nyanza that border on Lake Victoria6 and in these nine 
districts about 20% of women attending ante-natal clinics 
were infected with HIV in 2006, more than twice the rate 
in any other district including Mombassa and Nairobi. The 
countries in which the initial rate of increase was slowest 
                                                          
1  http://en.wikipedia.org/wiki/Mozambican_Civil_War. 
were Eritrea, Ethiopia, Malawi, Mozambique and 
Tanzania. 
 In many, but not all, countries the prevalence of 
infection fell significantly before the roll-out of ART 
began. The greatest proportional declines (Figure 4, 
second row, right) were seen in Eritrea and Ethiopia and 
Rwanda but the peak prevalence in these countries was 
low. Uganda and Zimbabwe are of particular interest; the 
peak prevalence was high, 12% and 25%, respectively, but 
then fell rapidly by about 50% before ART became 
available for reasons which are still not clear. In South 
Africa, Lesotho and Swaziland there is no evidence of any 
decline in prevalence prior to the roll-out of ART. 
 The scale up of ART in ESA has been impressive 
(Figure 4, third row left) leading to a further decline in the 
prevalence of HIV among people not on ART ranging 
from of about 25% in Angola, Lesotho and Mozambique 
to 65% in Ethiopia, Uganda and Zimbabwe. In Zimbabwe 
the combined effect of behaviour change and the 
availability of ART led to an 80% drop in the prevalence 
of people not on ART; almost enough to ensure 
elimination. 
 The data on TB are also informative. There is clearly a 
problem with Uganda where the rise in the TB notification 
rate (Figure 4, third row right) followed the rise in HIV 
prevalence by almost seven years. However the TB data 
for Uganda are weak and variable. In the other countries in 
the region the rise in TB follows the rise in HIV by about 2 
to 4 years although it is less than 2 in Namibia and the data 
for Rwanda are too uncertain to draw firm conclusions. 
 Finally, we note that the incidence rate ratio for TB 
varies greatly among countries (Figure 4, bottom) for 
reasons that are not understood. In Botswana, Eritrea, 
Ethiopia and Rwanda the incidence rate ratio is about 5; in 
Kenya, Malawi, Tanzania, Zambia and Zimbabwe it 
ranges from 25 to 35. 
Conclusions 
The data on HIV and TB in ESA are quite robust for most 
countries. Some countries need to review their data and all 
countries could expand their monitoring and routine 
surveillance systems to great advantage.  
 Probably the best surveillance in ESA is the series of 
annual surveys, starting in 1990, for women attending 
ante-natal clinics in South Africa.4 However, if these 
samples were tested, retrospectively for the presence of 
anti-retroviral drugs, viral loads, drug resistance and recent 
infections, it would be possible to assess the current state 
of the epidemic with much greater confidence and to make 
projections with much greater certainty.  
 All countries need to strengthen their patient 
monitoring systems and in this regard the Malawi 
Quarterly reports provide a good example and instructive 
lessons on how it should be done.7 For the island 
countries, where the prevalence is very low, better data are 
needed on the prevalence and size of the ‘key populations’ 
which are probably driving the epidemic in those places. 
 This analysis depends on the validity of the estimates 
of ART coverage in each country. However, it will be 
increasingly important to distinguish between the 
cumulative number of people of have ever started 
6 
treatment and the number that remain on treatment at any 
given time. Very few data are available anywhere in the 
region to give us great confidence in these numbers and 
suitable surveillance should be put in place to remedy this 
situation. 
Comoros, Seychelles, South Sudan 
Very limited data are available for either HIV or TB in the 
Comoros (Figure 1), the Seychelles or South Sudan. Better 
surveillance data for both infections and for key 
populations are needed. 
Madagascar 
There are better data on HIV in Madagascar (Figure 1) but 
the UNAIDS model suggests the prevalence was very low, 
always below about 0.6%, and flat from 1995 to 2007, 
after which it began to decline rapidly. This is quite unlike 
the pattern seen in any other country in ESA and deserves 
further investigation. About 1% of people infected with 
HIV are on ART. The TB data are limited and better 
surveillance for TB is needed. Better surveillance data for 
both infections and for key populations are needed. 
Mauritius 
The adult prevalence of HIV in Mauritius (Figure 1) has 
remained below about 1% but shows no sign of decline. 
About 14% of people infected with HIV are on ART and if 
this is expanded it should be possible to keep the 
prevalence at very low levels. The TB data are limited and 
better surveillance for TB is needed. Better surveillance 
data for both infections and for key populations are 
needed. 
Angola 
The revised data for HIV in Angola (Figure 3) suggest that 
the epidemic started later than in most other countries in 
ESA, has remained below about 2.5% but shows no sign 
that there has been any significant change in risky 
behaviour. About 19% of people infected with HIV are on 
ART and coverage needs to be expanded. Given the low 
prevalence of HIV the rise in TB notification rates seems 
to be disproportionately high. This should be investigated 
further but if relatively small numbers of people in 
concentrated areas are a risk of both infections, this would 
artificially inflate the incidence rate ratio for TB in those 
with HIV.8 
Botswana 
Botswana has experienced the most severe epidemic in 
ESA with a peak prevalence of HIV in the general 
population of about 25%. There seems to be little evidence 
of changes in behaviour that would have lead to a 
reduction in HIV transmission but the roll-out of ART has 
been very successful and about 60% of people infected 
with HIV are on ART making it the highest in the region. 
This will have substantially reduced the incidence of AIDS 
related TB by about 50%. Botswana now needs to move 
towards earlier treatment for HIV. 
Eritrea 
The epidemic of HIV in Eritrea peaked at just over 2% and 
the data suggest that there was a substantial change in 
behaviour which brought down the prevalence by about 
75% and about 40% of people infected with HIV are on 
ART. However, the data underlying the UNAIDS 
estimates are weak and better data surveillance is needed. 
Finding the relatively few remaining cases will be 
challenging and the immediate need is to find out who the 
at-risk people are and develop efficient strategies to find 
them and offer them treatment. It should be possible to end 
AIDS in Eritrea. 
Ethiopia 
The situation in Ethiopia is similar to that in Eritrea. The 
peak prevalence was about 3%, changes in behaviour seem 
to have reduced transmission by about 75% the about 48% 
of people infected with HIV are on ART. As in Eritrea the 
challenge is to find the relatively few remaining cases and 
develop efficient strategies to find them and offer them 
treatment. It should also be possible to end AIDS in 
Ethiopia. 
Kenya 
The epidemic of HIV in Kenya spread rapidly in the early 
years and peaked at an adult prevalence of about 9%. 
Behaviour change in Kenya seems to have reduced the 
prevalence by about 37% and about 38% of people 
infected with HIV are on ART. This has, in turn, reduced 
AIDS related TB by about 50%. It is of particular interest 
to note that nine districts in Kenya, bordering on Lake 
Victoria but excluding Busia, account for 10% of the 
Kenyan population but 30% of the HIV infections6 and 
successful control of HIV will depend on how HIV is dealt 
with in these nine districts. 
Lesotho 
Lesotho is a small country heavily dependant on South 
Africa socially and economically. The peak prevalence of 
HIV was 22%, the epidemic started late but then spread 
very rapidly. There is no evidence that changing behaviour 
has had any impact on HIV but 28% of people infected 
with HIV are now on ART and there are indications that 
AIDS related TB is beginning to fall. A key issue for 
Lesotho is migration to and from South Africa, especially 
in relation to the gold and platinum mines, and successful 
control of HIV will depend on control in South Africa. 
Malawi 
Malawi was among the first countries in ESA to 
experience the epidemic of HIV. It is of interest to note 
that in 1987 HIV testing was done on workers on the 
South African gold mines in which correlations were made 
between their HIV status and their country of origin.9 The 
men in the study came from South Africa, Malawi, 
Lesotho, Mozambique, Swaziland and Botswana but 
notably not from Rhodesia, now Zimbabwe. The 
prevalence amongst mine-workers from Malawi was 4%; 
among those from all other countries, including South 
Africa, it was about 0.03%. As a result the Chamber of 
Mines stopped recruiting novices from Malawi10 and the 
number of Malawians employed on the South African 
mines fell from 13,090 in 1988 to 2,212 in 1989.11 The 
peak prevalence of HIV in Malawi was about 15% but 
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changes in behaviour reduced the prevalence of HIV by 
about 32% and about 38% of people infected with HIV are 
on ART. Malawi has a very good patient monitoring 
system7 but needs to expand access to ART. 
Mozambique 
The epidemic of HIV in Mozambique started later than in 
other countries in ESA and reached a peak prevalence of 
11%. There seems to have been a small reduction in the 
prevalence as a result of changes in behaviour and 20% of 
all people infected with HIV are on ART. While this is a 
good start, ART needs to be made much more widely 
available. Furthermore, the recent and currents efforts to 
open up large areas of northern Mozambique to mining 
could increase the spread of HIV and this should be 
considered and monitored very carefully. 
Namibia 
The epidemic of HIV in Namibia started late and reached a 
peak prevalence of 14%. Behaviour change appears to 
have reduced the prevalence of HIV by about 9%. There 
has been a successful roll-out of ART and about 51% of 
people infected with HIV are on ART. With a relatively 
small population concentrated in relatively small 
geographical regions of the country a substantial increase 
in the roll-out of ART should bring the epidemic in 
Namibia under control. 
Rwanda 
The epidemic of HIV in Rwanda started early but was 
relatively modest a with peak prevalence just below 6%. 
Behaviour change appears to have reduced the prevalence 
by about 51% and the roll-out of ART has been very 
successful with 56% of infected people being on ART. 
Unfortunately the TB data are unreliable. However, if 
ART coverage is expanded Rwanda should be in a good 
position to end AIDS. 
South Africa 
South Africa accounts for about 16% of all people living 
with HIV in the world and control in the world depends 
critically on control in South Africa. The epidemic reached 
a peak prevalence of 15% but ranging from about 8% in 
the Western Cape to about 26% in KwaZulu/Natal. The 
epidemic started later than in the rest of the world but once 
HIV was established the rate of spread was relatively fast. 
There is no evidence of any reduction in HIV prevalence 
arsing from changes in behaviour but about 35% of people 
living with HIV are now on ART. While South Africa has 
the biggest ART programme in the world, further steps are 
needed to increase ART coverage further. There are 
indications that ART is already beginning to reduce the TB 
notification rate which has fallen by about 25%. Given the 
lack of evidence that changes in behaviour have had any 
impact on HIV in South Africa an ambitious policy of 
early treatment will be needed to control the epidemic. 
Swaziland 
The epidemic of HIV in Swaziland is dependent on the 
epidemic in South Africa but has reached an even higher 
peak prevalence of HIV of 25% and HIV spread even 
more quickly than in South Africa. As in South Africa 
there is no evidence for any reduction in the prevalence of 
HIV arising from changes in behaviour but the provision 
of ART has had a substantial impact and 42% of all people 
living with HIV are on ART. There is some evidence that 
ART is beginning to reduce the TB notification rate. As in 
South Africa an ambitious policy of early treatment will be 
needed to control the epidemic. 
Tanzania 
The epidemic of HIV in Tanzania peaked at about 7% but 
there is evidence that changes in behaviour reduced HIV 
prevalence by about 40% and 29% of people living with 
HIV are not on ART. With further expansion of ART 
Tanzania should be able to control the epidemic. 
Uganda 
Uganda was one of the first countries in the world to 
experience the full force of the HIV epidemic and the 
prevalence rose to a peak of about 12%. However, there 
was early evidence of a substantial change in people’s 
behaviour leading to a decline in the prevalence of HIV of 
about 57% and about 38% of people living with HIV are 
on ART. However, Uganda remains the only country in 
the region with evidence of a significant upsurge in the 
prevalence of HIV and it is important that this is 
confirmed and, if found to be a real, understood. At 
present the best explanation is that as people became 
aware of AIDS related mortality they were less likely to 
engage in high-risk sex but as the prevalence fell, and with 
it the AIDS related deaths, people became more 
complacent about high-risk sex. Modelling studies5 show 
that this could produce oscillations of precisely this kind 
but the question demands further investigation. 
Zambia 
 In Zambia the prevalence of HIV peaked at about 14% 
and there seems to have been some change in behaviour 
leading to a 13% drop in the prevalence of HIV. The scale 
up of HIV has been relatively successful and 45% of 
people living with HIV are now on ART. Zambia has now 
adopted a policy of early treatment and if this is effective 
there is every reason to believe that Zambia will be able to 
control the epidemic of HIV. 
Zimbabwe 
The epidemic of HIV in Zimbabwe reached the second 
highest levels in the region, just after Botswana, with a 
prevalence of HIV of 25% in 1997. However, there 
appears to have been a very rapid and substantial response 
with behaviour change leading to a 45% reduction in 
prevalence and 45% of people living with HIV are not on 
ART. This alone should bring the epidemic close to the 
elimination threshold and if the availability of ART is 
increased further, elimination of HIV in Zimbabwe should 
be assured. Because the response to the epidemic of HIV 
in Zimbabwe happened so early there is clear evidence that 
this has led to a 50% decline in AIDS related TB. 
Desiderata 
Progress in responding to and managing HIV in ESA has 
been considerable even though the region contains some of 
8 
the poorest countries with the highest rates of HIV in the 
world (Figure 4, top left). The roll-out of ART has been 
particularly striking and this has led to a reduction in the 
prevalence of people living with HIV who are not on ART, 
and consequently of the incidence of HIV, of about 50% 
but ranging from about 25% to 75% (Figure 4, third row, 
left). But many puzzles remain and much still needs to be 
done. 
 In some countries there is clear evidence that the 
prevalence of HIV began to fall rapidly well before ART 
became available or prevention programmes, such as 
medical male circumcision or vaginal microbicides, were 
in place.5 Epidemiological models show that this decline in 
the number of people living with HIV was too great to be 
the result of people dying of AIDS. There must have been 
changes in people’s behaviour or in the social structure 
and networks that facilitate the spread of infection to 
account for this observation. It is equally clear that in other 
countries such changes did not occur. At the moment there 
is no convincing explanation as to what these changes 
were, what factors facilitated or hindered them, and why 
the response was so variable across the region. For want of 
a better understanding we have gathered these effects into 
the overall rubric of ‘behaviour change’. 
 We need to understand the geographical heterogeneity 
in infections rates. This is illustrated most directly in 
Kenya where a 2006 survey of about half-a-million 
women attending ante-natal clinics showed that there are 
nine districts, bordering Lake Victoria, which have 10% of 
the total population but 30% of the people living with 
HIV.6 
 A further, equally puzzling aspect of the epidemic is 
the variability in the incidence rate ratio for TB if people 
have HIV. Being infected with HIV increases the risk of 
getting TB by about 30 times in Zambia and Zimbabwe 
but only by about 5 times in Botswana, Rwanda and 
Uganda. This dramatic difference is in urgent need of 
explanation. 
 What then still needs to be done? First, much better 
surveillance data on the prevalence of HIV and ART, of 
the incidence of HIV, and of the extent of viral load 
suppression in those on ART is needed. Second, much 
better patient monitoring isx needed in order to understand 
and, if needs be, address problems associated with the 
ART treatment cascade and ensure acceptability of testing, 
and high levels of treatment uptake, compliance and viral 
load suppression. Third, these data should be used to 
estimate and better understand the current state of the 
epidemics, to make projections into the future, to explore 
the consequences of different intervention strategies for 
managing and ultimately controlling HIV. All of this must 
include a good understanding of all of the costs to the 
patients, to the health services, to the work-force and to the 
state. Fourth, convincing strategies, that be sold to 
politicians and funding agencies, must be developed so 
that the epidemic of  AIDS can be ended.12 
  
Appendix 1 
Table 1. The raw data for Angola that were used by UNAIDS to estimates the time-trend in the prevalence of HIV. The data give the percent 
prevalence of HIV in women attending ante-natal clinics in different years and provinces 
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